Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandutinib in Newly Diagnosed AML Ineligible for Standard Induction
NCT00297921Phase 2Withdrawn
- Sponsor
- Millennium Pharmaceuticals
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label trial of tandutinib in acute myeloid leukemia (AML) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall Response Rate. Status: withdrawn.
02
Drugs
tandutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00297921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297921.